圣达生物(603079) - 2023 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2023 was ¥169,278,694.33, representing a decrease of 8.58% compared to the same period last year[5]. - The net profit attributable to shareholders was ¥3,491,046.45, down 83.22% year-on-year[5]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥768,830.17, a decline of 105.34%[5]. - The basic and diluted earnings per share were both ¥0.02, reflecting a decrease of 83.33%[6]. - The net profit for Q1 2023 was CNY 3,271,632.91, a significant decrease of 84.0% compared to CNY 20,395,348.28 in Q1 2022[22]. - The company achieved a total profit of CNY 5,575,375.89, down from CNY 23,676,663.82 in the same quarter last year[22]. - The company reported a net profit margin of approximately 0.75% for Q1 2023, compared to 9.0% in Q1 2022, indicating a decline in profitability[20]. Cash Flow and Liquidity - The net cash flow from operating activities was -¥49,775,808.03, indicating a significant cash outflow[6]. - The company reported a net cash outflow from operating activities of CNY -49,775,808.03, worsening from CNY -11,335,230.05 in Q1 2022[24]. - Cash and cash equivalents as of March 31, 2023, were RMB 279,068,031.81, down from RMB 320,717,851.36 at the end of 2022, representing a decrease of 12.9%[17]. - Cash and cash equivalents at the end of Q1 2023 were CNY 260,029,482.88, down from CNY 296,238,667.03 at the end of Q1 2022[25]. - Investment activities resulted in a net cash outflow of CNY -57,724,177.90, compared to CNY -182,830,411.59 in Q1 2022[25]. Assets and Liabilities - Total assets at the end of the reporting period were ¥1,615,005,744.91, down 2.43% from the end of the previous year[6]. - Total assets as of March 31, 2023, were RMB 1,615,005,744.91, down from RMB 1,655,207,544.77 at the end of 2022, a decrease of 2.4%[19]. - Total liabilities decreased to RMB 268,288,501.34 from RMB 311,761,934.11, a reduction of 13.9%[19]. - The company's equity attributable to shareholders increased slightly to RMB 1,331,488,386.18 from RMB 1,327,997,339.73, an increase of 0.1%[19]. - Short-term borrowings were reduced to RMB 10,007,300.00 from RMB 32,642,669.33, a significant decrease of 69.4%[18]. Operating Costs and Expenses - Total operating costs for Q1 2023 were RMB 168,012,041.08, slightly up from RMB 167,206,511.12 in Q1 2022, indicating a marginal increase of 0.5%[20]. - The company incurred a total operating expense of CNY 230,012,747.88, an increase from CNY 196,570,365.22 in the previous year[24]. - Research and development expenses increased to CNY 9,192,182.34, up 27.7% from CNY 7,196,029.08 in Q1 2022[24]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 15,547[12]. - The company received government subsidies amounting to ¥4,235,086.52, which were included in the current period's profit[9]. Market Conditions - The decline in net profit was primarily due to the continuous decrease in vitamin product prices and rising raw material costs[10].